Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 20;11(2):195.
doi: 10.3390/antiox11020195.

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Sun Joo Cha  1 , Kiyoung Kim  1   2
Affiliations
Review

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Sun Joo Cha et al. Antioxidants (Basel). .

Abstract

Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to treat amyotrophic lateral sclerosis. The distinguishing pathogenic features of neurodegenerative diseases include high reactive oxygen species levels and mitochondrial dysfunction. However, the correlation between mitochondria and edaravone has not been elucidated. This review highlights recent studies on novel therapeutic perspectives of edaravone in terms of its effect on oxidative stress and mitochondrial function.

Keywords: amyotrophic lateral sclerosis; antioxidant; edaravone; mitochondria; neurodegenerative disease; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Edaravone modulates mitochondrial function. Neurodegenerative diseases, including AD and PD are characterized by mitochondrial dysfunction. Treatment with edaravone restores mitochondrial functions through various mechanisms, such as the recovery of mitochondrial membrane potential, ATP levels, and mitochondrial morphology, and regulation of mitochondrial fusion/fission and mitochondrial biogenesis-related genes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918–1929. doi: 10.1111/ene.14393. - DOI - PMC - PubMed
    1. Mehta P., Antao V., Kaye W., Sanchez M., Williamson D., Bryan L., Muravov O., Horton K. Prevalence of amyotrophic lateral sclerosis—United States, 2010–2011. MMWR Suppl. 2014;63:1–13. - PubMed
    1. Jun K.Y., Park J., Oh K.W., Kim E.M., Bae J.S., Kim I., Kim S.H. Epidemiology of ALS in Korea using nationwide big data. J. Neurol. Neurosur. Psychiatry. 2019;90:395–403. doi: 10.1136/jnnp-2018-318974. - DOI - PMC - PubMed
    1. Grant P., Song J.Y., Swedo S.E. Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder. J. Child Adolesc. Psychopharmacol. 2010;20:309–315. doi: 10.1089/cap.2010.0009. - DOI - PMC - PubMed
    1. Schultz J. Disease-Modifying Treatment of Amyotrophic Lateral Sclerosis. Am. J. Manag. Care. 2018;24:S327–S335. - PubMed

LinkOut - more resources